Integrated Analysis of Prognostic Gene Expression Profiles from Hepatitis B Virus-Positive Hepatocellular Carcinoma and Adjacent Liver Tissue

Kim, Bu Yeo; Suh, Kyung Suk; Lee, Je Geun; Woo, Seon Rang; Park, In-Cheol; Park, Sun Hoo; Han, Chul Ju; Kim, Sang Bum; Jeong, Sook Hyang; Yeom, Young Il; Yang, Suk Jin; Kim, Chang Min; Cho, Su Jin; Yoo, Young; Cho, Myung‐Haing; Jang, Ja June; Choi, Dong Wook; Lee, Kee Ho

doi:10.1245/s10434-011-1709-0

Cited by 9 publications

(14 citation statements)

References 34 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier invasion studies using siRNAs were conducted under conditions of decreased proliferation and increased cell death, which potentially contributed to the decrease in the invasion activity of cancer cells (17)(18)(19)(20). Using HCC microarray datasets, we have evaluated several molecular markers differentially expressed in HCC (21)(22)(23). In the present study, we revealed that PRMT5 was overexpressed in HCC and colorectal cancer tissues and its depletion suppressed the invasion of cancer cell lines without affecting the colony survival.…”

Section: Protein Arginine Methyltransferase 5 Is Implicated In the Agmentioning

confidence: 62%

Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells

et al. 2018

Self Cite

View full text Add to dashboard Cite

Protein arginine methyltransferase 5 (PRMT5) is a protein that catalyzes transfer of methyl groups to the arginine residues of proteins and is involved in diverse cellular and biological responses. While the participation of PRMT5 in cancer progression has been increasingly documented, its association with the invasive phenotype currently remains poorly understood. In the present study, we revealed that PRMT5 is overexpressed in human hepatocellular carcinoma (HCC) and in colon cancer and its depletion leads to the suppression of cell invasive activity via the reduction of the expression of MMP-2. Real-time quantitative RT-PCR analysis of 120 HCC patient tissues revealed the overexpression of PRMT5 in HCC and the association of PRMT5 with aggressive clinicopathological parameters, such as poorer differentiation (P=0.004), more frequent hepatic vein invasion (P=0.019), larger tumor size (P=0.011) and higher α-fetoprotein levels (P=0.020). Similarly to the data obtained with HCC, overexpression of PRMT5 was also displayed in colon cancer tissues, compared to matched non-tumor regions. Consistent with the significant association of the overexpression of PRMT5 with hepatic vein invasion in patient specimens, PRMT5 depletion via siRNA transfection led to a marked reduction in the invasion rate in both HCC and colon cancer cells. Reduced invasion associated with PRMT5 depletion was accompanied by a decrease in the expression of MMP-2. Collectively, our results indicated that PRMT5 overexpression in HCC and colon cancer cells contributed to their acquisition of aggressive characteristics, such as invasiveness, thus presenting a promising therapeutic target for the treatment of these diseases.

show abstract

Section: Protein Arginine Methyltransferase 5 Is Implicated In the Agmentioning

confidence: 62%

Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Each batch of EHBH-Sh samples was further divided into two subgroups, which are typical low-risk (LRM) and high-risk metastatic (HRM) HCC as defined in previous reports (14,15). Patients in LRM group were defined as: (i) primary HCC without venous metastases, even in endoscopic vision; and (ii) no recurrence within 2 years after liver resection.…”

Section: Selection Modeling and Validation Of Metastasis Signaturementioning

confidence: 99%

The Prediction of Clinical Outcome in Hepatocellular Carcinoma Based on a Six-Gene Metastasis Signature

Yuan

Wang

Yang

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Recent gene signature studies are summarized in Table 1. [49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66] Gene signatures developed in those studies were used to separate patients into 2 or more subgroups with different clinical outcomes, phenotypes, and altered signaling pathways. The methods of developing gene signatures fall into two major groups.…”

Section: Gene Signaturesmentioning

confidence: 99%

“…Most of the gene signature studies belong to this group. [50,52,53,55,57,59,[61][62][63][64][65] The second group of gene signatures concerning defined phenotypes or signaling pathways was derived from the data of cell or animal model studies. [49,51,56,58,60] For examples, Lee et al [49] developed a gene signature of stemness from the gene profiling data of rat fetal liver tissue and Kaposi-Novak et al [51] developed a gene signature of Met signaling pathway using the Met deficient mouse model.…”

Section: Gene Signaturesmentioning

confidence: 99%

“…Kim et al [64] n = 56 (training, South Korea) n = 40 (validation, South Korea) limits the application of a single mutation. For example, RB1 somatic mutation can serve as an independent predictor for poor cancer-specific survival (HR 2.5, 95% CI: 1.05-5.93, P = 0.038) and early recurrence (OR 3.93, 95% CI: 1.29-11.90, P = 0.015).…”

Section: The Distribution Combination and Dynamic Patterns O F D R mentioning

confidence: 99%

See 1 more Smart Citation

Novel predictive and prognostic strategies of hepatitis B virus related hepatocellular carcinoma

Liu¹,

Yang²,

Shao³

et al. 2016

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignancy and an important cause of cancer death worldwide. Chronic hepatitis B virus (HBV) infection is the major cause of HCC. Recent studies of HBV-induced carcinogenesis not only discovered many new biomarkers but also developed a novel theory: Cancer Evolution-Development (Cancer Evo-Dev). Cancer Evo-Dev provides an evolutionary insight of developing more reasonable predictive and prognostic strategies. Characterizing chronic inflammatory microenvironment of cancer evolution, genetic polymorphisms of inflammatory factors, and HCC-related HBV mutations that negatively selected by host immunity may help greatly in identifying HBV-infected individuals who are more likely to develop HCC or benefit from HCC prophylactic options. Gene expression signatures and somatic mutation profiles reflect the different patterns of signaling pathway networks underlying tumor heterogeneity and can be applied to improve the molecular classification and prognostic stratification of HCC patients. Mutant cells that survive the selection can retro-differentiate into tumor initial cells and aggressive sub-clones. Detection of mutants or their hallmarks in cell-free DNA in peripheral blood potentially improve the early diagnosis, prognosis prediction, and personalized treatment of HBV-caused HCC.

show abstract

Integrated Analysis of Prognostic Gene Expression Profiles from Hepatitis B Virus-Positive Hepatocellular Carcinoma and Adjacent Liver Tissue

Cited by 9 publications

References 34 publications

Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells

Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells

The Prediction of Clinical Outcome in Hepatocellular Carcinoma Based on a Six-Gene Metastasis Signature

Novel predictive and prognostic strategies of hepatitis B virus related hepatocellular carcinoma

Contact Info

Product

Resources

About